Mary Ann E. Moore Sells 8,108 Shares of Pediatrix Medical Group, Inc. (NYSE:MD) Stock

Pediatrix Medical Group, Inc. (NYSE:MD) EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Pediatrix Medical Group Stock Performance

Shares of MD stock traded down $0.46 during mid-day trading on Tuesday, reaching $15.50. The stock had a trading volume of 490,907 shares, compared to its average volume of 869,960. Pediatrix Medical Group, Inc. has a 1-year low of $6.62 and a 1-year high of $16.41. The company has a current ratio of 1.42, a quick ratio of 1.38 and a debt-to-equity ratio of 0.83. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -5.21, a PEG ratio of 2.26 and a beta of 1.55. The business’s fifty day moving average is $12.19 and its 200-day moving average is $9.69.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.29 earnings per share. On average, research analysts forecast that Pediatrix Medical Group, Inc. will post 1.25 earnings per share for the current year.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of hedge funds have recently made changes to their positions in MD. Quest Partners LLC increased its holdings in shares of Pediatrix Medical Group by 25.6% in the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after purchasing an additional 622 shares during the last quarter. nVerses Capital LLC acquired a new stake in Pediatrix Medical Group during the second quarter worth $31,000. Innealta Capital LLC acquired a new stake in shares of Pediatrix Medical Group in the second quarter valued at $33,000. Nisa Investment Advisors LLC grew its stake in shares of Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after buying an additional 1,524 shares in the last quarter. Finally, CWM LLC grew its stake in shares of Pediatrix Medical Group by 134.0% in the third quarter. CWM LLC now owns 6,427 shares of the company’s stock valued at $74,000 after buying an additional 3,681 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Analyst Ratings Changes

MD has been the subject of several recent research reports. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Mizuho boosted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. Truist Financial upped their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a research report on Monday, November 4th. UBS Group upped their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of “Hold” and an average target price of $16.10.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.